Women's Health

HPV16 antibodies cause regression of cervical neoplasia

Published in Vaccine Weekly, November 6th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - Neutralizing antibodies against human papillomavirus 16 (HPV16) appear to cause regression of cervical intraepithelial (CIN) lesions and may even eliminate lesions in some cases.

Kei Kawana and colleagues at the University of Tokyo assigned 76 women to one of four categories based upon their cervical pathology, normal (n=7), CIN1 (n=37), CIN2 or CIN3 (n=19), or cervical cancer (n=13). Serum samples from the subjects were tested for neutralizing antibodies against HPV16 using HPV16-pseudovirions.

Women with normal cervical pathology were significantly more likely (p<0.0001) to have HPV16...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry